Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 198,359 | 110,623 | 127,177 | 167,634 | 249,427 |
| Marketable Securities | 64,231 | 114,448 | 146,504 | 168,662 | 137,386 |
| Receivables | 4,471 | 3,348 | 1,658 | 641 | 5,186 |
| Inventories | 10,657 | 10,154 | 10,192 | 5,065 | 5,629 |
| TOTAL | $285,330 | $246,117 | $293,883 | $354,604 | $406,427 |
| Non-Current Assets | |||||
| PPE Net | 23,496 | 24,661 | 22,029 | 21,092 | 20,766 |
| Intangibles | 198,142 | 202,298 | 206,455 | 210,619 | 214,801 |
| Other Non-Current Assets | 132,578 | 58,087 | 59,461 | 54,560 | 33,953 |
| TOTAL | $354,216 | $285,046 | $287,945 | $286,271 | $269,520 |
| Total Assets | $639,546 | $531,163 | $581,828 | $640,875 | $675,947 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,020 | 10,603 | 8,038 | 8,176 | 7,079 |
| Accrued Expenses | 25,315 | 39,558 | 38,887 | 31,405 | 27,101 |
| Other current liabilities | 3,064 | 3,020 | 3,179 | 3,159 | 3,140 |
| TOTAL | $71,066 | $67,289 | $65,874 | $58,248 | $50,838 |
| Non-Current Liabilities | |||||
| Long Term Debt | 377,951 | N/A | N/A | N/A | N/A |
| Deferred Revenues | 8,980 | 9,362 | 10,941 | 9,862 | 9,046 |
| Other Non-Current Liabilities | 93,338 | 321,251 | 322,035 | 321,279 | 305,895 |
| TOTAL | $542,939 | $395,403 | $395,792 | $396,392 | $380,862 |
| Total Liabilities | $614,005 | $462,692 | $461,666 | $454,640 | $431,700 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 72,768 | 71,453 | 71,795 | 71,830 | 71,529 |
| Common Shares | 72 | 72 | 72 | 72 | 71 |
| Retained earnings | -1,462,294 | -1,397,952 | -1,334,854 | -1,260,478 | -1,188,281 |
| Other shareholders' equity | -59 | -18 | -3 | -2 | 0 |
| TOTAL | $25,541 | $68,471 | $120,162 | $186,235 | $244,247 |
| Total Liabilities And Equity | $639,546 | $531,163 | $581,828 | $640,875 | $675,947 |